Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Valeant Pharmaceuticals International rose 95 cents (1.6%) to $59.03 on average volume. Throughout the day, 1.5 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in a price between $58.01-$59.05 after having opened the day at $58.02 as compared to the previous trading day's close of $58.08. Other companies within the Drugs industry that increased today were: Cardiome Pharma Corporation ( CRME), up 32.8%, Alimera ( ALIM), up 29.1%, Theratechnologies ( THER), up 19.1%, and Lifevantage Corporation ( LFVN), up 18.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $18.06 billion and is part of the health care sector. The company has a P/E ratio of 740.8, above the S&P 500 P/E ratio of 17.7. Shares are up 26.9% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Valeant Pharmaceuticals International a buy, one analyst rates it a sell, and four rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the negative front, Ariad Pharmaceuticals ( ARIA), down 20.7%, Lpath ( LPTN), down 18.8%, MEI Pharma ( MEIP), down 18.8%, and Novogen ( NVGN), down 18.4%, were all laggards within the drugs industry with Allergan ( AGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home